Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 1.00 |
| ▸ | KDM4A | O75164 | 3/20 | 0.69 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.69 |
| ▸ | KDM5A | P29375 | 1/20 | 0.69 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.69 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9835077 | 0.95 | ALOX5 (1.00) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL10691673 | 0.86 | ALOX5 (0.90) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL28234595 | 0.83 | ALOX5 (0.73) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL9833833 | 0.81 | ALOX5 (1.00) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL10695244 | 0.81 | ALOX5 (1.00) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL7129964 | 0.80 | ALOX5 (0.66) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL9662985 | 0.79 | ALOX5 (0.97) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL9836112 | 0.79 | ALOX5 (0.67) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL386559 | 0.79 | ALOX5 (0.77) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL9504638 | 0.78 | ALOX5 (0.64) | ALOX5HDAC1HDAC3HDAC7HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812010-A2 | USE OF NA+/ K+-ATPASE INHIBITORS AND ANTAGONISTS THEREOF | BTG International Limited (GB) | 2007-08-01 | — | — | EP | claimed |
| WO-2006044916-A2 | USE OF NA+/ K+-ATPASE INHIBITORS AND ANTAGONISTS THEREOF | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-5861268-A | ENZYME INHIBITORS AND CELLS | BIOMIDE INVESTMENT LIMITED PARTNERSHIP (US) | 1999-01-19 | — | — | US | claimed |
| US-20220257614-A1 | USE OF 12-LIPOXYGENASE INHIBITORS IN THE TREATMENT OF COVID-19 | NEW YORK MEDICAL COLLEGE | 2022-08-18 | — | — | US | disclosed |
| US-20170327827-A1 | ADIPOCYTE-SPECIFIC CONSTRUCTS AND METHODS FOR INHIBITING PLATELET-TYPE 12 LIPOXYGENASE EXPRESSION | THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER (IL) | 2017-11-16 | — | — | US | disclosed |
| US-9663790-B2 | Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression | THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER (IL) | 2017-05-30 | — | — | US | disclosed |
| US-9279127-B2 | Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression | THE MEDICAL RESEARCH FUND AT THE TEL-AVIV SOURASKY MEDICAL CENTER (IL) | 2016-03-08 | — | — | US | disclosed |
| US-20150191734-A1 | ADIPOCYTE-SPECIFIC CONSTRUCTS AND METHODS FOR INHIBITING PLATELET-TYPE 12 LIPOXYGENASE EXPRESSION | THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER (IL) | 2015-07-09 | — | — | US | disclosed |
| EP-2078079-B1 | ADIPOCYTE-SPECIFIC CONSTRUCTS AND METHODS FOR INHIBITING PLATELET-TYPE 12 LIPOXYGENASE EXPRESSION | MEDICAL RES AND INFRASTRUCTURE FUND OF THE TEL AVIV SOURASKY MEDICAL CT (IL) | 2011-05-04 | — | — | EP | disclosed |
| US-20110038923-A1 | ADIPOCYTE-SPECIFIC CONSTRUCTS AND METHODS FOR INHIBITING PLATELET-TYPE 12 LIPOXYGENASE EXPRESSION | THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER (IL) | 2011-02-17 | — | — | US | disclosed |
| EP-2078079-A2 | ADIPOCYTE-SPECIFIC CONSTRUCTS AND METHODS FOR INHIBITING PLATELET-TYPE 12 LIPOXYGENASE EXPRESSION | The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center (IL) | 2009-07-15 | — | — | EP | disclosed |
| EP-1812010-A2 | USE OF NA+/ K+-ATPASE INHIBITORS AND ANTAGONISTS THEREOF | BTG International Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| US-20060135443-A1 | Use of Na*/K*-ATPase inhibitors and antagonists thereof | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006044916-A2 | USE OF NA+/ K+-ATPASE INHIBITORS AND ANTAGONISTS THEREOF | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1047437-A4 | SEA CUCUMBER CAROTENOID LIPID FRACTION PRODUCTS AND METHODS OF USE | COLLIN PETER DONALD (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6399105-B1 | LIPOXYGENASE INHIBITORS FOR INFLAMMATORY AUTOIMMUNE DISEASES | COLLIN PETER DONALD (US) | 2002-06-04 | — | — | US | disclosed |
| EP-1047437-A1 | SEA CUCUMBER CAROTENOID LIPID FRACTION PRODUCTS AND METHODS OF USE | Collin, Peter Donald (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999037314-A1 | SEA CUCUMBER CAROTENOID LIPID FRACTION PRODUCTS AND METHODS OF USE | COLLIN PETER DONALD (US) | 1999-07-29 | — | — | WO | disclosed |
| US-5861268-A | ENZYME INHIBITORS AND CELLS | BIOMIDE INVESTMENT LIMITED PARTNERSHIP (US) | 1999-01-19 | — | — | US | disclosed |
| US-5861268-A | ENZYME INHIBITORS AND CELLS | BIOMIDE INVESTMENT LIMITED PARTNERSHIP (US) | 1999-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135443-A1 | Use of Na*/K*-ATPase inhibitors and antagonists thereof | ATP1A4, ATP1A2, ATP6V1B2 | ALOX5 4133/4885KDM4A 604/4885KDM4C 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.